Aparna Balasubramanian, MD, assistant professor of medicine, Johns Hopkins School of Medicine, and attendee of the CHEST Annual Meeting 2023, talks about the necessity of challenging measurements like race-specific equations that can create harmful assumptions.
Aparna Balasubramanian, MD, assistant professor of medicine, division of pulmonary and critical care, Johns Hopkins School of Medicine, discusses the need to contest previously held beliefs, such as the use of race-specific equations that can help detect chronic obstructive pulmonary disease (COPD). Balasubramanian is attending the CHEST Annual Meeting 2023, where themes of equity are woven throughout the agenda.
Transcript
Some of your studies focus on how disparities impact pulmonary care. One study called "Early Evidence of COPD Obscured by Race-Specific Prediction Equations" found that race-specific equations underestimate disease severity amongst African-Americans, with these effects especially evident in early disease and might result in late COPD detection.
What are some ways race-specific equations can be rectified, and how can they be implemented into clinical practice?
Race-specific equations are a result of observed epidemiologic data that suggest that average lung function is lower among Blacks than in Whites. So generally, the race-specific equations were meant to account for that. But that has led to an assumption that that lower lung function is expected or normal among Black individuals. This study specifically was trying to demonstrate that by using these equations and buying into that assumption, we underestimate disease severity and underdiagnose disease in specifically COPD. The field was really working very hard at trying to identify reasonable alternatives to address this issue, because obviously, we don't want to be propagating a method for interpretation of lung function that is harmful to one specific community, one specific population.
Current recommendations are to use a single reference equation, which is known as GLI Global, or the [Global Lung Function Initiative] global equation, for all races to try and mitigate the kind of selective underestimation that we just described. The benefit of that equation is that it treats low lung function values similarly across all races. Of course, that does sort of fall into a bin of a one-size-fits all. There's a lot of research surrounding alternatives that might be a little bit better that are a bit more conscientious of differences across populations.
I think, generally, the community is trying to think about non–reference equation–based methods for understanding lung function, things like using just FEV1 [forced expiratory volume in 1 second] in its absolute form, using something like FEV1Q [FEV1 quotient] or FEV1 over height squared, but there's a lot more work that has to be done in that arena. I think the other piece of this, in terms of rectifying the issues surrounding race-specific equations, is understanding how we apply race-specific equations and whether or not absolute thresholds or cutoffs make sense for qualifying for therapies or employment or disability.
AXS25: Health Policy, Drug Costs, and AI Highlights From the Conference
May 6th 2025Asembia’s AXS25 Summit covered a variety of relevant topics in the pharmaceutical industry, from the effects of the new administration to how artificial intelligence (AI) is reshaping the patience experience.
Read More
New Research Challenges Assumptions About Hospital-Physician Integration, Medicare Patient Mix
April 22nd 2025On this episode of Managed Care Cast, Brady Post, PhD, lead author of a study published in the April 2025 issue of The American Journal of Managed Care®, challenges the claim that hospital-employed physicians serve a more complex patient mix.
Listen
Addressing KRAS Resistance, RAS(ON) Therapies Find Limelight at AACR
May 5th 2025KRAS-targeted therapies, including daraxonrasib and zoldonrasib, show promise in overcoming resistance in cancer treatment, as highlighted at the 2025 meeting of the American Association for Cancer Research (AACR).
Read More
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
Community Oncology Reacts to Trump's Drug Pricing Executive Order
May 2nd 2025An executive order signed on Tuesday, March 15, necessitated a change in plans for this panel discussion from the 2025 Community Oncology Conference, with the assembled experts, moderated by Ted Okon, MBA, executive director of the Community Oncology Alliance, speaking to how the order would reverberate across the community oncology space.
Read More